TWI910161B - 蛋白質s抗體、其製造方法及其用途 - Google Patents

蛋白質s抗體、其製造方法及其用途

Info

Publication number
TWI910161B
TWI910161B TW110116287A TW110116287A TWI910161B TW I910161 B TWI910161 B TW I910161B TW 110116287 A TW110116287 A TW 110116287A TW 110116287 A TW110116287 A TW 110116287A TW I910161 B TWI910161 B TW I910161B
Authority
TW
Taiwan
Prior art keywords
seq
antibody
acid sequence
amino acid
protein
Prior art date
Application number
TW110116287A
Other languages
English (en)
Chinese (zh)
Other versions
TW202208443A (zh
Inventor
桑迪普 潘尼克
亞當 大衛 羅森塔爾
東尼 尚榮 卡
桂香 氏 董
Original Assignee
美商維加醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商維加醫療公司 filed Critical 美商維加醫療公司
Publication of TW202208443A publication Critical patent/TW202208443A/zh
Application granted granted Critical
Publication of TWI910161B publication Critical patent/TWI910161B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW110116287A 2020-05-05 2021-05-05 蛋白質s抗體、其製造方法及其用途 TWI910161B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063020505P 2020-05-05 2020-05-05
US63/020,505 2020-05-05
US202163169755P 2021-04-01 2021-04-01
US63/169,755 2021-04-01

Publications (2)

Publication Number Publication Date
TW202208443A TW202208443A (zh) 2022-03-01
TWI910161B true TWI910161B (zh) 2026-01-01

Family

ID=76076555

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110116287A TWI910161B (zh) 2020-05-05 2021-05-05 蛋白質s抗體、其製造方法及其用途
TW110116289A TW202208444A (zh) 2020-05-05 2021-05-05 蛋白質ｓ抗體、其製造方法及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110116289A TW202208444A (zh) 2020-05-05 2021-05-05 蛋白質ｓ抗體、其製造方法及其用途

Country Status (11)

Country Link
US (4) US12441810B2 (enExample)
EP (1) EP4146705A1 (enExample)
JP (1) JP2023524807A (enExample)
KR (1) KR20230019097A (enExample)
CN (1) CN115916835A (enExample)
AU (1) AU2021268943A1 (enExample)
CA (1) CA3177329A1 (enExample)
GB (1) GB2610720A (enExample)
IL (1) IL297947A (enExample)
TW (2) TWI910161B (enExample)
WO (2) WO2021226245A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12441810B2 (en) 2020-05-05 2025-10-14 Vega Therapeutics, Inc. Protein S antibodies, methods of making and uses thereof
GB202402535D0 (en) * 2024-02-22 2024-04-10 Imperial College Innovations Ltd Fusion proteins
WO2025240928A1 (en) * 2024-05-16 2025-11-20 Vega Therapeutics, Inc. Treatment of von willebrand disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160297892A1 (en) * 2013-11-07 2016-10-13 Novo Nordisk A/S Novel Methods and Antibodies for Treating Coagulapathy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187067A (en) 1986-12-15 1993-02-16 Teijin Limited Immunological determination of free human protein S and C4bp-protein S complex
US5366861A (en) 1987-08-12 1994-11-22 Teijin Limited Immunoassay and reagent kit used therefor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US6423313B1 (en) 1988-12-30 2002-07-23 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5321123A (en) 1991-07-02 1994-06-14 The Scripps Research Institute Protein S polypeptides and anti-peptide antibodies that inhibit protein S binding to C4B binding protein, diagnostic systems and therapeutic methods
ES2142317T3 (es) * 1991-07-02 2000-04-16 Scripps Research Inst Polipeptidos de proteinas s y uso de los mismos.
DK0658168T3 (da) 1992-08-27 2001-01-22 Sanquin Bloedvoorziening Antistoffer, som er specifikke for et hæmostatisk protein, anvendelse heraf til isolering af intakt protein, hæmostatiske p
US20030143759A1 (en) 1995-10-20 2003-07-31 Bjorn Dahlback Assays for determining anticoagulant cofactor activity
SE9604378D0 (sv) * 1996-11-27 1996-11-27 Tac Ab Methods and reagents for determining protein S
US6379975B1 (en) 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
US7053202B2 (en) * 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
US20030124118A1 (en) 2001-11-27 2003-07-03 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors
US20080057059A1 (en) 2001-11-09 2008-03-06 Novo Nordisk Healthcare A/G Pharmaceutical Composition Comprising Factor VII Polypeptides and Protein S Inhibitors
US20030165485A1 (en) 2001-11-09 2003-09-04 Goran Bertilsson Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells
WO2007008966A1 (en) 2005-07-12 2007-01-18 The Scripps Research Institute Elisa to detect multimeric forms of a protein
EP1920068A4 (en) 2005-07-28 2008-08-13 American Diagnostica Inc LUPIC ANTICOAGULANT TEST
EP1919499A2 (en) 2005-07-29 2008-05-14 Universiteit van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor
EP2217716A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS
EP2165710A1 (en) 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
CN106232615B (zh) * 2014-02-28 2021-06-01 3B制药有限公司 肽及其使用方法
US12441810B2 (en) 2020-05-05 2025-10-14 Vega Therapeutics, Inc. Protein S antibodies, methods of making and uses thereof
CN115884986A (zh) 2020-06-29 2023-03-31 Inserm(法国国家健康医学研究院) 抗蛋白s单域抗体和包含其的多肽
WO2024124136A1 (en) 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160297892A1 (en) * 2013-11-07 2016-10-13 Novo Nordisk A/S Novel Methods and Antibodies for Treating Coagulapathy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 B Dahlbäck et al Characterization of functionally important domains in human vitamin K-dependent protein S using monoclonal antibodies J Biol Chem 265(14) 1990 May 15 8127-8135 *

Also Published As

Publication number Publication date
US20230083243A1 (en) 2023-03-16
US20240425613A1 (en) 2024-12-26
CN115916835A (zh) 2023-04-04
AU2021268943A1 (en) 2022-11-24
EP4146705A1 (en) 2023-03-15
GB2610720A (en) 2023-03-15
WO2021226243A1 (en) 2021-11-11
US20230174672A1 (en) 2023-06-08
TW202208444A (zh) 2022-03-01
CA3177329A1 (en) 2021-11-11
US12441810B2 (en) 2025-10-14
GB202217381D0 (en) 2023-01-04
US12145999B2 (en) 2024-11-19
TW202208443A (zh) 2022-03-01
US12421320B2 (en) 2025-09-23
US20240084038A1 (en) 2024-03-14
KR20230019097A (ko) 2023-02-07
IL297947A (en) 2023-01-01
JP2023524807A (ja) 2023-06-13
WO2021226245A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
JP6342467B2 (ja) 組織因子経路インヒビターに特異的に結合することが可能な抗体
US20200384106A1 (en) Novel anti-human gpvi antibodies and uses thereof
US12421320B2 (en) Protein S antibodies, methods of making and uses thereof
CN105705517A (zh) 用于治疗凝血障碍的新方法和抗体
AU2021202612B2 (en) Inhibition of platelet aggregation using anti-human GPVI antibodies
JP6445440B2 (ja) 抗プロテインｃ抗体による出血性疾患の治療
US12630631B2 (en) Inhibition of platelet aggregation using anti- human gpvi antibodies
TW201617371A (zh) 針對經活化之因子ｖ之抗體
WO2014202993A1 (en) Binding motif for thrombin inhibitors